Equities

Trupanion Inc

Trupanion Inc

Actions
  • Price (EUR)30.55
  • Today's Change4.77 / 18.50%
  • Shares traded11.00
  • 1 Year change+66.21%
  • Beta--
Data delayed at least 15 minutes, as of May 17 2024 11:34 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Trupanion, Inc. is a provider of medical insurance for cats and dogs throughout the United States, Canada, Europe, Puerto Rico, and Australia. The Company operates in two segments: Subscription Business and Other Business. The Subscription Business segment includes subscription fees related to the Company's direct-to-consumer products. The Other Business segment comprises of other product offerings that generally have a business-to-business relationship and a different margin profile than its subscription segment, including writing policies on behalf of third parties and other products and software solutions. The Company’s core Trupanion product provides software that is designed to communicate directly with a veterinary hospitals practice management software. It provides Powered by Trupanion pet insurance product offerings marketed by third parties and, in Canada. The Company’s low and medium average revenue per unit (ARPU) products marketed under the brand Furkin and PHI Direct.

  • Revenue in USD (TTM)1.16bn
  • Net income in USD-26.77m
  • Incorporated2006
  • Employees1.14k
  • Location
    Trupanion Inc6100 4Th Avenue South, Suite 400SEATTLE 98108United StatesUSA
  • Phone+1 (888) 738-7478
  • Fax+1 (302) 636-5454
  • Websitehttps://trupanion.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.